Moleculin Biotech (NASDAQ: MBRX) to Begin Preparing Clinical Testing Sites for Leukemia Treatment

  • NASDAQ Biotechnology Index up and climbing
  • Developing new treatment for acute myeloid leukemia (AML)
  • Lead candidate, Annamycin, now at phase II

Since a rising sea lifts all boats, it’s decidedly good news for Moleculin Biotech, Inc. (NASDAQ: MBRX) that the NASDAQ Biotechnology Index (NBI) is enjoying a spring tide. The index has offered a year-to-date return of over 17 percent and seems set to keep climbing. This benign environment gives Moleculin an opportunity to advance work on its leading anti-cancer drug candidates. The company has begun to identify and prepare testing sites in Europe and has already appointed a Lead European Principal Investigator.

Moleculin was featured on Business Insider (, in a piece that attributed the rise in the NBI to ‘recent FDA decisions and clinical trial developments’. Moleculin, a preclinical pharmaceutical company focused on the development of anti-cancer drug candidates, announced on August 3 that it had selected Bioscience SA (Bioscience), a Polish contract research organization (CRO) to begin identifying and preparing clinical testing sites in Poland for Annamycin. Annamycin is the company’s drug candidate for the treatment of…


More from NetworkNewsWire

Medical Innovation Holdings, Inc. (MIHI) Serving the Underserved with Telemedicine

Qualstar Corp. (NASDAQ: QBAK) – Serving One of the Most Foundational Technical Markets on Earth

India Globalization Capital, Inc. (NYSE: IGC) – Blockbuster Position for Treating Alzheimer’s

About NetworkNewsWire

NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

For more information please visit

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published:

NetworkNewsWire (NNW)
New York, New York
212.418.1217 Office

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s